Quality improvement project to enhance heparin safety in patients with haemodialysis in China

BMJ Open Quality

article

Qiu-zhen Tan¹  Yan-fen Mai¹  Hai-hong Jiao¹  Ren-jie Xiong¹  Yu Liu¹  Li Lin²  Li-wen Cui¹  Pearl Pai¹ 

[1] Department of Medicine, Division of Nephrology , The University of Hong Kong-Shenzhen Hospital;Clinical Service Department , The University of Hong Kong-Shenzhen Hospital;Department of Medicine , Faculty of Medicine, The University of Hong Kong

关键词: Medication safety;    Incident reporting;    Patient safety;    Quality improvement;    Root cause analysis;   

DOI  :  10.1136/bmjoq-2021-001665

学科分类：药学

来源: BMJ Publishing Group

【 摘 要 】

Maintaining safety in a haemodialysis (HD)unit is paramount.1 Low-molecular-weightheparin (LMWH) is commonly used as ananticoagulant to prevent clot forming in theextracorporeal circuits (ECCs).2 3 Incorrectdosages of anticoagulant may bring risks topatients with HD. Presently, most HD unitsdetermine their own dosages of LMWHaccording to their own experience, andguided by clinical efficacy.4 Monitoring oflow-range activated clotting time (ACT-LR)and anti-Xa activity is rarely undertaken oravailable. Chinese national standard operational procedure (SOP) for HD has suggestedno specific LMWH regimen, leaving it tothe discretion of individual HD units.5 MostChinese dialysis units appear to have an arrayof heparin regimens of their own.

【 授权许可】

CC BY-NC|CC BY|CC BY-NC-ND